Touyun Biotech Group First Half 2025 Earnings: EPS: HK$0.007 (vs HK$0.013 loss in 1H 2024)

Touyun Biotech Group (HKG:1332) First Half 2025 Results

Key Financial Results

• Revenue: HK$31.5m (down 34% from 1H 2024).
• Net income: HK$19.4m (up from HK$35.5m loss in 1H 2024).
• Profit margin: 62% (up from net loss in 1H 2024).
• EPS: HK$0.007 (up from HK$0.013 loss in 1H 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Touyun Biotech Group shares are down 15% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Touyun Biotech Group (at least 3 which are significant), and understanding these should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.